VRCA Stock Price History and Quote Analysis Insights for Investors
Verrica Pharmaceuticals Inc.
Stock Price Today
Verrica Pharmaceuticals Inc. (VRCA) stock declined over -5.20%, trading at $0.76 on NASDAQ, down from the previous close of $0.80. The stock opened at $0.79, fluctuating between $0.72 and $0.85 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Company Information
| Employees | 100 |
| Beta | 1.46 |
| Sales or Revenue | $5.12M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) stock price is $0.76 in the last trading session. During the trading session, VRCA stock reached the peak price of $0.85 while $0.72 was the lowest point it dropped to. The percentage change in VRCA stock occurred in the recent session was -5.2% while the dollar amount for the price change in VRCA stock was -$0.04.
The NASDAQ listed VRCA is part of Biotechnology industry that operates in the broader Healthcare sector. Verrica Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Joe Bonaccorso
Chief Commercial Officer
Mr. Ted White
Pres, Chief Executive Officer & Director
Dr. Gary Goldenberg M.D.
Chief Medical Officer
Mr. P. Terence Kohler
Chief Financial Officer
Mr. Christopher G. Hayes
Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel
Mr. Eugene Scavola
Executive Vice President of Technical Operations
Dr. Bradley J. Catalone MBA, Ph.D.
Head of Drug Devel.
VRCA's closing price is 8.08% higher than its 52-week low of $0.70 where as its distance from 52-week high of $11.41 is -93.33%.
Number of VRCA employees currently stands at 100.
Official Website of VRCA is: https://www.verrica.com
VRCA could be contacted at phone 484 453 3300 and can also be accessed through its website. VRCA operates from 44 West Gay Street, West Chester, PA 19380, United States.
VRCA stock volume for the day was 538.84K shares. The average number of VRCA shares traded daily for last 3 months was 879.73K.
The market value of VRCA currently stands at $75.08M with its latest stock price at $0.76 and 98.68M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com